Cigarette smoke-induced LKB1/AMPK pathway deficiency reduces EGFR TKI sensitivity in NSCLC

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Smokers with non-small cell lung cancer (NSCLC) exhibit poorer prognosis and lower response rates to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs).
• The underlying mechanisms for this reduced sensitivity in smokers remain poorly understood.
• Understanding these mechanisms is crucial for developing effective treatment strategies for this patient subgroup.

Purpose of the Study:

• To investigate the molecular mechanisms by which cigarette smoke affects EGFR TKI sensitivity in NSCLC.
• To identify potential biomarkers for predicting TKI response in smokers with NSCLC.
• To explore novel therapeutic strategies combining EGFR TKIs with other agents.

Main Methods:

• Exposure of NSCLC cells with wild-type EGFR (EGFR^WT) to cigarette smoke extract (CSE).
• Analysis of glycolysis, AMP-activated protein kinase (AMPK) signaling, and mammalian target of rapamycin (mTOR) pathway.
• Assessment of liver kinase B1 (LKB1) expression and its regulation by CpG island methylation.
• Correlation analysis of LKB1 expression with TKI sensitivity in NSCLC patient data.
• In vitro studies combining EGFR TKI with AMPK activators.

Main Results:

• CSE exposure enhanced glycolysis and attenuated AMPK-dependent mTOR inhibition in NSCLC cells.
• CSE-induced repression of LKB1 expression via CpG island methylation reduced EGFR^WT NSCLC cell sensitivity to EGFR TKI.
• LKB1 expression levels positively correlated with TKI sensitivity in NSCLC patients.
• Combined treatment with EGFR TKI and AMPK activators demonstrated synergistic effects, increasing TKI sensitivity.

Conclusions:

• LKB1 methylation induced by cigarette smoke is a key mechanism underlying reduced EGFR TKI sensitivity in smokers with EGFR^WT NSCLC.
• LKB1 serves as a potential predictive biomarker for EGFR TKI sensitivity in this patient population.
• Combination therapy of EGFR TKI with AMPK activators represents a promising therapeutic strategy for EGFR^WT NSCLC in smokers.